CUHK Medicine

CUHK Medicine This is the official page of Faculty of Medicine, The Chinese University of Hong Kong (CUHK)

The history of the Faculty of Medicine can be traced back to the Government and Legislative Council’s approval in 1974 to establish a new medical school at The Chinese University of Hong Kong. The Faculty was set up to cope with the needs of society for graduates with solid and professional training in medical knowledge and competency. To date, there are 5 schools and 14 departments with 450 regul

ar teaching staff and 3,600 adjunct/honorary teaching staff in the Faculty offering teaching for the 8 undergraduate programmes and a number of postgraduate programmes. We also provide continuing and professional training to the public and healthcare professionals. So far, over 15,200 graduates and undergraduate students have been trained.

【國際醫科生研討會】中大首批四年制第二學位醫科課程學生文嘉希 (Ricky) 於今年六月參加由德國慕尼黑大學 (LMU) 所舉辦的第十屆醫科生研討會(Munich Medical Student Science Conference)，LM...
18/06/2026

【國際醫科生研討會】中大首批四年制第二學位醫科課程學生文嘉希 (Ricky) 於今年六月參加由德國慕尼黑大學 (LMU) 所舉辦的第十屆醫科生研討會(Munich Medical Student Science Conference)，LMU為Global Alliance for Medical Excellence的成員院校之一。此研討會是一項年度國際會議，聚集世界各地醫學院的大學生，旨在展示醫療衛生與生物醫學領域的各類研究成果，促進來自不同背景和院校的學生之間的交流。Ricky獲邀分享其關於生成式人工智能模型的研究成果。

以下是Ricky的分享：

「在人工智能時代，人與人之間的連結與思想交流，更顯珍貴。」

我很榮幸代表香港中文大學參加於德國慕尼黑大學（LMU）舉行的 2026 年慕尼黑醫科生研討會（MMS ScienceCon）。在來自世界各地逾百名醫科生中，我有幸成為 14 位演講者之一，分享我的研究項目《生成式人工智能模型於胸部電腦掃描中肺腫瘤檢測及特徵分析的評估》。此先導研究的成果將於國際醫學期刊《Cancers》發表。
作為四年制第二學位醫科課程（Graduate Entry Track, GET）的首屆學生，我特別感謝課程的靈活安排及中大醫學院的支持，讓我們在建立醫學知識基礎的同時，亦能積極參與科研、創新及國際交流。

參與 MMS ScienceCon 不僅是一場學術交流，更讓我有機會接觸不同領域的前沿研究，與來自不同文化背景的未來醫生交流觀點，並建立珍貴的友誼，共同致力推動醫療進步。隨着人工智能持續重塑醫療發展，我期望能為其臨床應用作出貢獻，推動創新，改善病人健康與完善醫療成果。

關於慕尼黑醫科生研討會
慕尼黑醫科生研討會是一個關於人類醫學、牙醫、流行病學及公共衛生的年度研討會。該會議每年六月在慕尼黑大學舉行，並開放予來自世界各地的學生參與。會議旨在讓來自不同醫療衛生及生物醫學領域的學生在不同學習階段上了解展示其科研成果的流程和要求。

關於中大四年制第二學位醫科課程 (Graduate Entry Track)
中大醫學院於2025年9月推出四年制第二學位醫科課程 (Graduate Entry Track，以下簡稱 GET)，名額25個，為立志行醫並已具備科學或醫學相關背景的人士提供嶄新的醫學培訓機會，與六年制的本科生醫學課程雙軌並行，培育出更多元的醫學人才，應對不斷上升的醫療人手需求。

有關四年制第二學位醫科課程 (GET)詳情請參閱：https://bit.ly/4i2nuAi

【International Student Science Conference】Ricky Man Ka-hei, a student from the first cohort of the Graduate Entry Track (GET) medical programme at The Chinese University of Hong Kong (CUHK), participated in the 10th Munich Medical Student Science Conference in June this year. The conference was organized by Ludwig-Maximilians-Universität München (LMU) in Germany, which is one of the member institutions of the Global Alliance for Medical Excellence. This MMS ScienceCon is an annual global event to provide a platform for presenting of research across the full spectrum of healthcare and biomedical science and for fostering dialogue between students from different backgrounds and institutions.

Ricky was invited to present his research findings on Generative AI Models.
Here are Ricky’s reflections on this conference:

“In the era of AI, human connection and the exchange of ideas are more valuable than ever.”

It was a great honour to represent The Chinese University of Hong Kong at the Munich Medical Student Science Conference (MMS ScienceCon) 2026, held at Ludwig-Maximilians-Universität (LMU) Munich. Among more than a hundred medical students from around the world, I was grateful to be one of 14 presenters, sharing my research project, “Evaluation of Generative AI Models for Lung Tumour Detection and Characterization on Chest CT.” Findings from this pilot study will be published in the international journal Cancers.

As a member of the inaugural cohort of CU Medicine’s 4-year Graduate Entry Track (GET) Medicine Programme, I am especially thankful for the flexibility of our curriculum and the support of our faculty, which encourage us to pursue research, innovation, and global engagement alongside our medical studies.

Participating in MMS ScienceCon allowed me to learn from inspiring research across diverse medical fields, exchange perspectives with future doctors, and build meaningful friendships grounded in a shared passion for advancing healthcare. As AI continues to reshape healthcare, I hope to contribute to its clinical integration and help advance a future where innovation improves health outcomes for all.

About the Munich Medical Student Science Conference
The MMS ScienceCon is a student conference for all students of human medicine, dentistry, epidemiology and public health. The conference takes place every year in June at LMU Munich and is also open to students from other universities worldwide. It aims at familiarising healthcare and biomedical science students at all stages of their studies with the processes and academic requirements of presenting research scientifically.

About Graduate Entry Track (GET)
In September 2025, CU Medicine launched a four-year second-degree medical programme—the Graduate Entry Track (GET)—with an intake quota of 25 places. This track offers a brand-new medical training opportunity for individuals who aspire to practice medicine and already possess a background in science or healthcare-related fields. Operating in parallel with the existing six-year undergraduate medical curriculum, GET aims to cultivate a more diverse cohort of medical talents to meet the steadily rising demand for healthcare professionals.

Details about Graduate Entry Track (GET): https://bit.ly/4i2nuAi

【揪出免疫治療耐藥性臥底】肝癌是本港癌症殺手第3位，有多達8成病人即使接受最先進的免疫治療，最終都會出現耐藥反應。醫學界多年來著力探究箇中耐藥機制，惟至今仍然很多未解之謎。 中大醫學院生物醫學學院鄭詩樂教授的團隊早於2023年揭示肝癌細胞如...
17/06/2026

【揪出免疫治療耐藥性臥底】肝癌是本港癌症殺手第3位，有多達8成病人即使接受最先進的免疫治療，最終都會出現耐藥反應。醫學界多年來著力探究箇中耐藥機制，惟至今仍然很多未解之謎。

中大醫學院生物醫學學院鄭詩樂教授的團隊早於2023年揭示肝癌細胞如何能「避開」免疫檢查點，以致對肝癌常用的ICB免疫療法出現耐藥。基於早前基礎研究結果，團隊最新發現一種名為TREM2+ LAM的免疫細胞，表面協助清除體內死亡細胞，卻從中抽取脂肪酸「餵食」癌細胞，更重新編程癌細胞的表達基因抵抗免疫攻擊，以增強腫瘤的耐藥性。

今次發現成功揪出協助肝癌細胞對抗ICB治療的「臥底」，團隊以此作為新靶點進行聯合免疫療法，亦證實可令小鼠體內的癌腫瘤縮小。團隊現正與製藥業商討籌備臨床研究，以證實抑制TREM2+ LAM的聯合免疫療法，具有精準治療的效用及安全性，料需2至3年時間會有結果。

詳情：https://bit.ly/4vY07Pa
全文：https://www.cell.com/cancer-cell/fulltext/S1535-6108(26)00250-3

【Digging out the undercover agent of immunotherapy resistance】Liver cancer is the third leading cause of cancer-related deaths in Hong Kong, with up to 80% of patients eventually develop resistance even after receiving the most advanced immunotherapy. For years, the medical profession has been striving to uncover the mechanisms behind this resistance, but many questions remain unanswered.

In 2023, a CU Medicine research team led by Professor Alfred Cheng Sze-lok from CU Medicine’s School of Biomedical Sciences revealed that liver cancer cells can evade the therapy-armed immune system, resulting in resistance to ICB, the most commonly used therapy for liver cancer. Building on this, the team has now uncovered an immune cell, TREM2+ LAM. While it appears to help clear dead cells, it also extracts fatty acids to "feed" cancer cells and reprogram their gene expression to resist immune attack, enhancing tumour drug resistance.

This discovery successfully identified the "undercover agent" that helps liver cancer cells resist ICB therapy. By targeting this cell in combination immunotherapy, the team managed to shrink tumours in mice. They are currently in discussions with pharmaceutical sector to prepare for clinical studies, aiming to confirm the efficacy and safety of combination immunotherapy targeting TREM2+ LAM as a precision treatment, with results expected in two to three years.

Details: https://bit.ly/3QjPt65
Full article: https://www.cell.com/cancer-cell/fulltext/S1535-6108(26)00250-3

【中大「腸胃及肝臟科」蟬聯全球第二】世界大學排名權威《美國新聞與世界報道》（U.S. News and World Report）最新公布「全球最佳大學學科排名2026-27」，中大醫學院的「腸胃及肝臟科」再度蟬聯全球第二，連續四屆穩佔全球...
16/06/2026

【中大「腸胃及肝臟科」蟬聯全球第二】世界大學排名權威《美國新聞與世界報道》（U.S. News and World Report）最新公布「全球最佳大學學科排名2026-27」，中大醫學院的「腸胃及肝臟科」再度蟬聯全球第二，連續四屆穩佔全球三強；與「內分泌及代謝科」一起連續五屆成為「亞洲之冠」。同時，「臨床醫學科」亦是連續第二年榮膺 「亞洲第一」 。

今年中大醫學院共有五個學科位列「亞洲三甲」 ，包括：
• 腸胃及肝臟科
• 內分泌及代謝科
• 臨床醫學科
• 外科
• 放射學、核子醫學及醫學影像科

共七個學科位列「全港之冠」，分別是：
• 腸胃及肝臟科
• 內分泌及代謝科
• 臨床醫學科
• 外科
• 放射學、核子醫學及醫學影像科
• 腦神經科學及行為科
• 腫瘤科

中大醫學院院長趙偉仁教授表示：「中大醫學院作為全球最年輕的頂尖醫學院之一，能在國際排名中持續取得佳績，絕非僥倖，而是全體教職員、研究人員、臨床醫護團隊以及校友多年來默默耕耘、精益求精的成果。

尤其令人鼓舞的是，我們的腸胃及肝臟科連續多年位列全球三甲，最近兩年更是全球第二，這不僅是國際學術界對我們科研實力的肯定，更是對我們以科研推動臨床變革，以創新回應病人需要這一核心理念的最佳認同。

未來，我們將繼續深化跨學科協作，加速將實驗室的突破轉化為臨床應用，並積極培育具國際視野及人文關懷的21世紀好醫生。中大醫學院的目標，不僅是成為亞洲頂尖，更要成為全球醫療創新的重要引擎，為香港、國家乃至全人類的健康福祉作出更實質的貢獻。」

【CUHK's "Gastroenterology & Hepatology" Ranked World No. 2 Again】In the latest "Best Global Universities Subject Rankings 2026-27" released by the world university ranking body U.S. News & World Report, the Faculty of Medicine at The Chinese University of Hong Kong has once again secured the world's No. 2 position in "Gastroenterology & Hepatology," maintaining its place among the global top three for four consecutive editions. Together with "Endocrinology & Metabolism", both subjects have been crowned "Asia's Best" for five consecutive terms. Meanwhile, "Clinical Medicine" has also been ranked "Asia's No. 1" for the second straight year.

This year, five subjects from CU Medicine have made it into the "Top Three in Asia," including:
•⁠ ⁠Gastroenterology & Hepatology
•⁠ ⁠Endocrinology & Metabolism
•⁠ ⁠Clinical Medicine
•⁠ ⁠Surgery
•⁠ ⁠Radiology, Nuclear Medicine & Medical Imaging

A total of seven subjects have been ranked "Top in Hong Kong," namely:
•⁠ ⁠Gastroenterology & Hepatology
•⁠ ⁠Endocrinology & Metabolism
•⁠ ⁠Clinical Medicine
•⁠ ⁠Surgery
•⁠ ⁠Radiology, Nuclear Medicine & Medical Imaging
•⁠ ⁠Neuroscience & Behavior
•⁠ ⁠Oncology

Professor Philip CHIU, Dean of Medicine at CUHK, remarked: “CU Medicine’s strong performance in international rankings reflects years of sustained effort from its faculty, researchers, clinical teams and alumni.

Our Gastroenterology and Hepatology discipline has ranked among the world’s top three for several consecutive years and second globally for the past two years, underscoring both its research strength and its commitment to using innovation to improve patient care.

Looking ahead, we will continue to strengthen interdisciplinary collaboration, accelerate the translation of research into clinical application, and nurture doctors with global vision and humanistic care. We aspire not only to be Asia's best, but also to become a key engine of global healthcare innovation, making more tangible contributions to the health and well-being of Hong Kong, the nation, and humanity at large."

俠醫仁心(62)：醫工圓桌會議 (上)中大醫學院院長趙偉仁教授外科手術機械人的概念源自50多年前，美國太空總署提出如果太空人在太空站內患上外科疾病，身處地球的外科醫生能夠利用遠程手術機械人為太空人開刀，太空總署轄下實驗室更為這個概念申請了專...
15/06/2026

俠醫仁心(62)：醫工圓桌會議 (上)
中大醫學院院長趙偉仁教授

外科手術機械人的概念源自50多年前，美國太空總署提出如果太空人在太空站內患上外科疾病，身處地球的外科醫生能夠利用遠程手術機械人為太空人開刀，太空總署轄下實驗室更為這個概念申請了專利。然而，要在太空做手術，不單需要外科技術，麻醉和術後護理同等重要；在未來，當醫學技術能從具身智能手術機械人，演化成為「自動化機械人手術艙」，太空探險遇上緊急疾病時便能透過全自動化外科手術醫治。

太空技術看似遙不可及，然而重要成果如互聯網技術，卻已從太空轉化落地，成為我們日常生活一部分。手術機械人在上世紀90年代開始研究轉化為民用，當中機械人和控制台獨立的設計，就是源自遙距手術的概念。

今年4月我在首爾參加「韓國內鏡、腹腔鏡及機械人外科學會」30周年會議，認識了手術機械人及遠程醫療之父、美國國家工程院院士王友侖（Yulun Wang）。友侖的主題演講非常精彩，提及他在1989年開發出全世界首台單獨手術機械臂AESOP，能根據醫生口述指令操控腹腔鏡，更是全球首台獲得美國認證的手術機械人系統。當年我在聯合醫院工作時，亦曾經使用AESOP輔助微創手術。

在1990年，他成立了Computer Motion公司，研發出外科手術機械人ZEUS和遠距醫療設備，促成全球首個跨國家遠程手術。另一間公司Intuitive Surgical在1995年構建外科手術機械人Da Vinci Surgical System早期原型，並在2003年收購Computer Motion，整合雙方的專利與設計。Da Vinci手術機械人自2000年問世以來，已廣泛應用於泌尿科、普通外科、婦科及心臟科手術上。

全球首次遠程機械人手術在2001年9月7日開展，由身處紐約的法國微創手術權威Professor Jacques Marescaux操刀，利用友侖研發的ZEUS手術機械人，為身在法國的病人切除膽囊。這次跨越大西洋的遠程手術命名為Lindbergh Operation，以紀念1927年全球首位單獨飛越大西洋的飛機師Charles Lindbergh。參與支援手術的除了友侖和工程師外，亦包括法國電信公司提供穩定網絡。當年互聯網不如今天發達，在工程師眼中網絡速度和機械人穩定度是遠程手術的限制，外科醫生則最關心網絡操控機械人的延誤及機器臂的精準度。機械人遠程膽囊切除術在45分鐘內完成，其間網絡延誤少於150毫秒，令外科醫生安全地完成手術，病人兩天後出院，成為外科手術的世界創舉。

我和友侖談論時發現，互聯網技術一日千里，5G引領着通訊科技創新，然而遠程手術發展卻停滯不前。原因之一，是手術機械人只由一間科技公司主導發展，而技術創新需要投入大量資源，這跟上市公司的盈利和股價並不對等，而在沒有競爭的情况下，公司看不到創新發展的重要。根據友侖分析，全球現時已有超過270個手術機械人平台，引入競爭之餘亦能推動下世代手術機械人的發展。我們都認為遠程手術將是重點之一，但發展方向不會像過往的模式：外科主刀醫生飛到外國為自己國家的病人做手術，或外科主刀醫生跨國家為外地病人做手術。前者只是一種演示，沒有實際臨牀需要，而後者則涉及醫學執照與倫理等問題。未來遠程手術發展方向應是「跨中心監督和指導的遙距手術」，為世界各地年輕醫生提供新手術的指導和支持，同時提升病人在手術中的安全。年輕醫生一般能掌握95%手術操作，但剩餘5%最關鍵或最困難的程序，需要專家和教授的指導，遙距機械人手術監督和指導系統能提供隨時隨地聯繫的平台，支援年輕醫生在手術中遇上的困難。專家在大部分情况下只需一兩個動作便能化解困難，亦能為年輕醫生傳授秘訣。

虎父無犬子，友侖開創手術機械臂AESOP的聲控概念，源自他的父親——世界著名語言學家王士元教授。王教授1933年在上海出生，1965年受聘於加州大學伯克萊分校成為教授，創辦「音韻實驗室」、「語言分析研究所」。他在1995年移居香港，2005年加入中文大學，任電子工程學系、語言學及現代語言系、東亞研究中心的研究教授。當我得知友侖來港探望93歲父親時，決定宴請兩位世界著名的學者出席「中大醫工圓桌會議」午餐，與我和中大工程學院歐國威教授，討論醫療機械人、人工智能及遠程手術的未來發展。（待續）

(原文刊載於明報)

【晚期肺癌變成「慢性病」】肺癌是本港頭號癌症殺手，每年有逾6,000宗新症。肺癌患者中，接近八成為非小細胞肺癌（NSCLC），其中約百分之四屬ALK陽性個案。 中大醫學院與全球多間癌症中心共同領導一項長達七年的大型國際三期臨床研究，結果顯示...
10/06/2026

【晚期肺癌變成「慢性病」】肺癌是本港頭號癌症殺手，每年有逾6,000宗新症。肺癌患者中，接近八成為非小細胞肺癌（NSCLC），其中約百分之四屬ALK陽性個案。

中大醫學院與全球多間癌症中心共同領導一項長達七年的大型國際三期臨床研究，結果顯示未接受過治療的晚期ALK陽性非小細胞肺癌患者，使用第三代標靶藥Lorlatinib作一線治療，超過一半七年間病情沒有惡化，此成果是迄今為止所有針對晚期實體腫瘤的標靶治療中，報告過的最長無惡化存活期。這意味著隨著醫學的不斷進步，將因某些基因異常而引起的晚期肺癌轉化為「慢性病」、讓患者得以「與病共存」的願景，正一步步成為現實。

肺癌轉移至腦部十分常見，當中帶有ALK基因變異的非小細胞肺癌患者超過30%會出現腦轉移，唯傳統放射治療在控制腦轉移和長期存活方面效果有限。Lorlatinib被證實具有極強的穿透血腦屏障的能力，整體而言，治療超過30個月後的患者沒有出現新的腦部惡化病例，七年無顱內惡化機率高達92%，，Lorlatinib更成功令96%原本沒有腦轉移的患者在七年內沒有出現腦轉移，幾乎完全預防了新發腦轉移。

中大醫學院腫瘤學系系主任莫樹錦教授剛在2026年美國臨床腫瘤學會年會(2026 ASCO Annual Meeting) 上發表此項驚人發現，研究成果並同時刊登於國際權威醫學期刊《腫瘤學年鑑》（Annals of Oncology）。

詳情：https://bit.ly/4vybsVI
研究全文：https://www.annalsofoncology.org/article/S0923-7534(26)00876-8/fulltext

【Turning advanced lung cancer into a chronic disease】Lung cancer is the leading cause of cancer-related deaths in Hong Kong, with more than 6,000 new cases diagnosed annually. NSCLC accounts for nearly 80% of all lung cancer cases, of which about 4% are ALK-positive.

CU Medicine co-led a landmark seven-year international Phase 3 clinical trial in lung cancer with multiple cancer centres worldwide. The study demonstrated that more than half of previously untreated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) experienced no disease progression after receiving the third-generation targeted therapy lorlatinib as first-line treatment at seven years. This represents the longest progression-free survival (PFS) ever reported among targeted therapies for advanced solid tumours. The findings mark a significant step toward transforming specific oncogene-driven advanced lung cancer into a chronic condition, enabling patients to live with the disease.

Brain metastases are highly prevalent among lung cancer patients, affecting more than 30% of cases with ALK gene mutations. Conventional radiotherapy offers limited efficacy in controlling brain metastases or achieving long-term survival. Lorlatinib has demonstrated exceptional blood-brain barrier pe*******on capabilities. No new cases of brain progression were observed after more than 30 months of treatment, and the rate of no new intracranial progression at seven years was as high as 92%. 96% of patients without brain metastases at the start of treatment did not develop intracranial progression over the seven years. These findings suggest that lorlatinib provides substantial protection against the development of brain metastases.

The breakthrough results were presented by Professor Tony Mok, Chairman of the Department of Clinical Oncology at CU Medicine, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the leading international medical journal Annals of Oncology.

Details: https://bit.ly/4vF42QK
Full article: https://www.annalsofoncology.org/article/S0923-7534(26)00876-8/fulltext

【智慧醫療新里程】中大醫學院研究團隊與康諾思騰 （Cornerstone Robotics） 合作自主研發的「Sentire思騰®腔鏡手術機械人」，近日已獲中大醫院正式引入，至今已完成超過160宗手術。我們成功將先進科研成果轉化為臨床醫療技...
09/06/2026

【智慧醫療新里程】中大醫學院研究團隊與康諾思騰 （Cornerstone Robotics） 合作自主研發的「Sentire思騰®腔鏡手術機械人」，近日已獲中大醫院正式引入，至今已完成超過160宗手術。我們成功將先進科研成果轉化為臨床醫療技術，與中大醫院攜手開創智慧醫療與微創手術新里程，利用先進醫療科技惠及更多病患。

自2020年起，中大醫學院透過InnoHK創新香港研發平台獲香港特區政府資助，成立了醫療機械人創新技術中心（MRC），並在2022年8月起與康諾思騰展開合作，開展Sentire思騰®腔鏡手術機械人臨床研究， 範疇涵蓋上消化道外科、結直腸外科和泌尿外科等多項專科手術。

在臨床應用方面，Sentire思騰®腔鏡手術機械人目前已用於泌尿外科及一般外科手術，未來將擴展至婦科、胸腔外科、胃腸外科、肝膽外科、心臟科等多項專科。相比傳統手術，機械人手術具備創口小、康復快、術中出血量少及併發症風險較低的優勢；同時，微創內視鏡手術器械有助提升醫生進行手術的靈活性，並提供清晰銳利的視野，有助確保手術精準安全。

中大研究團隊目前正利用這套機械人系統研究具身人工智能（embodied AI）的應用，未來具身人工智能有望與外科醫生協同工作，共同作出最合適的臨床決策，以安全完成複雜的機械人手術。


【New Milestone in Smart Healthcare】The Sentire® Surgical System co-developed by the researchers from CU Medicine and Cornerstone Robotics, has been introduced at the CUHK Medical Centre (CUMC), where over 160 surgeries have been performed since its introduction. CU Medicine has successfully translated the innovative research results into clinical application, marking a significant milestone in smart healthcare and minimally invasive surgery with CUMC.

In 2020, CU Medicine received funding support from the Government of the HKSAR’s InnoHK to establish the Multi-scale Medical Robotics Center (MRC). Since August 2022, the center has been collaborating with Cornerstone Robotics to conduct clinical trials on the system, covering upper gastrointestinal surgeries, colorectal surgeries and urological surgeries.

In terms of clinical applications, the Sentire® Surgical System is currently applied in urology and general surgery and will be extended to multiple specialties in the future, including gynaecology, thoracic surgery, gastrointestinal surgery, hepato-biliary-pancreatic surgery, and cardiology. Compared to traditional surgery, robotic surgery offers smaller incisions for faster recovery, reduces blood loss, and lowers complication risks. Furthermore, minimally invasive endoscopic surgical instruments allow surgeons to operate with enhanced flexibility as well as a clear and sharp visibility which ensures safe and precise surgery.

The CUHK research team is currently investigating embodied AI using this robotic system. In the future, embodied AI is envisioned to serve as a co-pilot with surgeons in making the most appropriate clinical decisions to ensure the safe performance of complex robotic surgeries.

08/06/2026

【中大醫學院人工智能與醫學教育】想知道 AI 如何成為中大醫學院的「最強隊友」嗎？🤖

人工智能（AI）不再是遙不可及的未來科技，它正以前所未有的速度重塑醫療面貌。在中大醫學院，AI 已逐步融入日常醫學教育，從提升課堂學習體驗、協助臨床模擬訓練，到支援各項科研項目。AI 不僅讓學生學習更有效率，也能幫助老師提升教學成效。

在第一集，我們將帶大家了解中大醫學院影像及介入放射學系如何運用 AI 協助學生學習，並探討人工智能研究實習 (AIRI) 計劃如何致力培育結合醫療與科技的新一代專才。

想知更多？密切留意下一集，我們將繼續帶大家探索 AI 如何全面融入中大醫學教育！

完整影片：https://youtu.be/TH1A7awh678?si=wDuNbS0_SKnxZ7_n

【CU Medicine Artificial Intelligence in Medical Education】Ever wondered how AI has become the ultimate study sidekick at CU Medicine? 🤖

Artificial Intelligence (AI) is no longer a distant concept - it is reshaping the healthcare landscape at an unprecedented pace. At the CUHK Faculty of Medicine, AI is already part of everyday medical education. From enhancing classroom learning and hands-on simulations to supporting research projects, it helps students learn more effectively while enabling teachers to teach more efficiently.

In this first episode, we explore how AI supports students in the Department of Imaging and Interventional Radiology, and how the AI Research Internship (AIRI) Programme is nurturing a new generation of specialists who seamlessly blend medicine with AI.

Curious to know more? Stay tuned for the next episode to discover even more ways AI is integrated into CU Medicine’s education!

Full video: https://youtu.be/TH1A7awh678?si=wDuNbS0_SKnxZ7_n

#香港中文大學 #中大 #中大醫學院
#人工智能 #醫學創科 #醫學教育 #醫療科技

【年輕科研人才】中大醫學院共有三位傑出學者分別榮獲 2026/27 年度香港研究資助局（研資局）「海外研究學者計劃」及「新晉學者計劃」資助，充分彰顯醫學院在科研創新及人才培育方面的卓越實力。藥劑學院副教授吳濰龍教授榮獲研資局今年新設的「海外...
06/06/2026

【年輕科研人才】中大醫學院共有三位傑出學者分別榮獲 2026/27 年度香港研究資助局（研資局）「海外研究學者計劃」及「新晉學者計劃」資助，充分彰顯醫學院在科研創新及人才培育方面的卓越實力。

藥劑學院副教授吳濰龍教授榮獲研資局今年新設的「海外研究學者計劃」，將獲資助前往海外開展研究項目，以提升學術知識與研究能力。此外，何善衡傳染病研究中心博士後研究員陳展博博士和微生物學系博士後研究員朱恒彦博士也同獲「新晉學者計劃」資助，全面支援他們在香港投身研究工作。

中大醫學院將會繼續為科研學者提供優良的研究環境，支持他們將尖端科研成果轉化為切實的解決方案，造福社會。

詳情：https://bit.ly/4dRq3Wp

關於「海外研究學者計劃」

為研資局今年新設的資助項目，現以試行形式運作三個學年，旨在促進教資會資助大學的國際化發展，鼓勵學者赴海外進行沉浸式國際合作研究，拓寬香港學術界的國際視野，加深對海外研究趨勢的了解，同時提升本地大學的國際聲譽。

關於「新晉學者計劃」

旨在鼓勵本地及海外博士畢業生留港或來港投身研究工作，在教資會資助大學投身研究工作，為具潛質的研究人員在事業早期提供支援，並延展支援至於計劃期內晉升為助理教授或研究助理教授者，以培育、挽留及擴大研究人才庫，支持香港推動研發及培養研究文化。


【Young Research Talents】Three CU Medicine scholars have been awarded funding under the Hong Kong Research Grants Council’s (RGC) Overseas Research Fellowship Scheme (ORFS) and Junior Research Fellow Scheme (JRFS) for the 2026/27 academic year, highlighting CU Medicine’s outstanding achievements in scientific innovation and talent cultivation.

Professor Billy Ng, Associate Professor from the School of Pharmacy has been awarded the ORFS, a new funding initiative launched by the RGC this year, which provides support for him to conduct research projects overseas and enhance academic knowledge and research capabilities. Dr CHAN Chin-pok, Postdoctoral Fellow of the S.H. Ho Research Centre for Infectious Diseases and Dr ZHU Hengyan, Postdoctoral Fellow of the Department of Microbiology have both been awarded the JRFS funding, providing them with comprehensive support on their research journeys in Hong Kong.

CU Medicine will continue to provide an ideal environment for our scholars, supporting them in translating cutting-edge research findings into practical solutions for the benefit of society.

Details: https://bit.ly/4e61B2a

About Overseas Research Fellowship Scheme (ORFS)

The ORFS is a new funding initiative launched by the RGC this year, operating on a pilot basis for three academic years. It aims to promote internationalisation of UGC-funded universities, encourage scholars to visit overseas institutions for immersive international collaborative experiences, helping them broaden their global perspective and deepen their understanding of research trends beyond Hong Kong, and boost the visibility of Hong Kong universities.

About Junior Research Fellow Scheme (JRFS)

The JRFS aims at providing promising local and non-local postdoctoral researchers at UGC-funded universities with support at a pivotal time in their very early career, as well as supporting their transition, as applicable, in taking up Assistant Professor (Asst P) or Research Assistant Professor (RAP) positions at UGC-funded universities during the fellowship period, so as to nurture and expand a pool of research talents with a view to propelling research and development in Hong Kong and fostering a research culture.

【首位香港學者】恭賀中大醫學院陳重娥教授獲亞洲糖尿病研究協會（AASD）「清野裕傑出領袖獎」，成為首名獲頒此最高榮譽的香港學者，表揚她於亞洲糖尿病教研的卓越貢獻及終身成就﹗ 頒獎典禮早前於日本大阪舉行，AASD讚揚陳教授於糖尿病流行病學、早...
05/06/2026

【首位香港學者】恭賀中大醫學院陳重娥教授獲亞洲糖尿病研究協會（AASD）「清野裕傑出領袖獎」，成為首名獲頒此最高榮譽的香港學者，表揚她於亞洲糖尿病教研的卓越貢獻及終身成就﹗

頒獎典禮早前於日本大阪舉行，AASD讚揚陳教授於糖尿病流行病學、早發性糖尿病領域的全球領導地位，其領導的「亞洲糖尿病評估計劃」及《刺針》糖尿病委員會，促進亞洲糖尿病研究及護理的發展。她將研究轉化並以數據策動，透過展示大規模實證結構及目標導向的糖尿病護理成效，亦對臨床實踐有著直接影響。

陳教授感謝所有支持她的老師、團隊、合作夥伴、病人及家人，並強調糖尿病是可防可治，醫生科學家正是推動精準醫療、預防及教育發展不可或缺的一環。重要在於為年輕一代鋪設成為醫生科學家的職涯路徑，兼具臨床實踐及科研能力，推動以預防為目標的醫療護理及教育發展。

陳教授多次獲頒國際獎項及殊榮，包括2011年獲中國科技部頒發「中國女醫師協會五洲女子科技獎（臨床醫學科研創新獎）」，並於2019年及去年獲美國糖尿病協會頒授國際年度獎「2019 Harold Rifkin 糖尿病傑出國際服務獎」及「2025凱利·韋斯特流行病學獎」。

詳情：https://bit.ly/4o7feD0

【First Hong Kong scholar】Congratulations to Professor Juliana CHAN Chung-ngor on being the first Hong Kong scholar to receive the Yutaka Seino Distinguished Leadership Award from the Asian Association for the Study of Diabetes （AASD）! This prestigious award recognises her lifetime achievements and outstanding contributions to diabetes research and care across Asia.

The award ceremony was held recently in Osaka, Japan. Professor Chan is recognised for her global leadership in diabetes epidemiology and young-onset diabetes, including her leadership of the JADE Programme and the Lancet Commission on Diabetes, which has advanced diabetes research and care across Asia. Her translational, data-driven work has directly influenced clinical practice by demonstrating the impact of structured, target-driven diabetes care at scale.

Professor Chan expressed her heartfelt thanks to her mentors, colleagues, research team, collaborators, patients, and her family for their support throughout her research journey. She emphasised that diabetes is both preventable and treatable, and that physician-scientists are essential for advancing precision medicine, prevention, and educational development. She highlighted the importance of establishing career paths for the next generation to become physician-scientists who integrate clinical practice and research, thereby advancing preventive healthcare and education.

In recognition of her remarkable work, Professor Chan has received numerous international accolades, including the China Medical Women’s Association Wuzhou Women Sciences & Technology Award (2011), the 2019 Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes, and the 2025 Kelly West Epidemiology Award from the American Diabetes Association.

Details: https://bit.ly/4uTWUQt

【推動全民健康覆蓋】中大醫學院賽馬會公共衞生及基層醫療學院醫療體系及政策研究所（CHSPR）聯同亞太地區醫療系統強化網絡（ANHSS）合辦「以私人醫療保險促進可持續醫療融資以推動全民健康覆蓋」區域知識交流活動，匯聚逾200位來自亞太地區的政...
03/06/2026

【推動全民健康覆蓋】中大醫學院賽馬會公共衞生及基層醫療學院醫療體系及政策研究所（CHSPR）聯同亞太地區醫療系統強化網絡（ANHSS）合辦「以私人醫療保險促進可持續醫療融資以推動全民健康覆蓋」區域知識交流活動，匯聚逾200位來自亞太地區的政策制定者、監管機構代表、學者及業界領袖進行交流及分享。

隨著人口老化及醫療成本持續上升，全球各地的醫療衞生系統正面臨日益沉重的財政壓力。各國政府及政策制定者正探索多元化的融資模式，在保障全民公平獲得優質醫療服務的同時，維持長遠的財政可持續性。

各地專家剖析私人醫療保險在促進可持續醫療融資中的策略性作用，並探討如何補足公共融資安排，以提升醫療服務的可負擔性、公平性及系統韌性。分享嘉賓亦從政策與監管、醫療體系設計，以及業務與營運角度，探討私人醫療保險作為可持續融資工具的可行條件與發展方向。

詳情: https://bit.ly/4a4A688

[A great step forward for universal health coverage] The Centre for Health Systems & Policy Research (CHSPR) in the Jockey Club School of Public Health and Primary Care at CU Medicine, in collaboration with the Asia-Pacific Network for Health Systems Strengthening (ANHSS), has recently brought over 200 policymakers, regulators, academics and industry leaders across the Asia-Pacific region together for a knowledge exchange in the event titled “Private Health Insurance for Sustainable Health Financing to Advance Universal Health Coverage”.

With ageing populations and rising healthcare costs, health systems around the world are facing growing financial pressures. Governments and policymakers are increasingly exploring diverse financing approaches to maintain equitable access to quality healthcare, while safeguarding long-term fiscal sustainability.

Experts have examined the strategic role of private health insurance in sustainable health financing, particularly how it can complement public financing arrangements to ensure affordability, equity, and system resilience. Policy and regulatory considerations, health system design, as well as business and operational perspectives, have also been discussed to better understand the conditions under which private health insurance can function as a sustainable complementary financing tool.

Details: https://bit.ly/4dNBPkI

Address

Choh-Ming Li Basic Medical Sciences Building, The Chinese University Of Hong Kong, Shatin
New Territories

Website

Alerts

Be the first to know and let us send you an email when CUHK Medicine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category